FOLH1 and neoplasm: Two years later, the same group observed in patients with metastatic castration-resistant prostate cancer, the decrease of the tumor burden in liver and of disseminated bone marrow metastases after TAT using a prostate-specific membrane antigen (PSMA) ligand labeled with 225Ac (2).